KOSUNI CRYPTO
Korea's Crypto Pulse, in English
$BTC $ETH $XRP $SOL $DOGE
Market Analysis
Neutral

Goldman Sachs: Big Pharma Turning to Chinese Biotech for Assets as Patents Expire

Published October 7, 2026 11:19 AM · 6 views $SUMM $LILY
Goldman Sachs: Big Pharma Turning to Chinese Biotech for Assets as Patents Expire

Goldman Sachs has stated that big pharma companies will lose $10 billion worth of drug patents by 2032, prompting them to source assets from Chinese biotech firms. The bank's U.S. biotech lead analyst Salvin Richter said Chinese competitors could shorten Western pharmaceutical product cycles.

China's five-year pharmaceutical plan, announced on September 18, aims for at least 25% market share of first-in-class innovative drugs by 2030. These drugs work through new mechanisms rather than improving existing medications.

AstraZeneca recently agreed to invest $2 billion in U.S.-listed Summit Therapeutics, which licenses its key oncology drug from China's Akeso. Licensing deals for Chinese pharmaceuticals have surpassed $12 billion this year, a 36% increase from last year, according to Xinhua.

Richter told CNBC that much of the Chinese research still focuses on improving existing drugs, which could lead to oversupply in the market. She also noted that Chinese developers are targeting the obesity market, similar to Eli Lilly's recent stock surge.

Richter mentioned that acquirers will likely pay a lower premium for biotech firms outside China relative to market capitalization. In another point, she highlighted Summit Therapeutics' HARMONi-3 lung cancer trial comparing its drug with Merck's Keytruda, which could confirm whether Chinese data applies to Western patients.

Summit expects next data on squamous cell lung cancer in the second half of 2026. After a mid-April analysis showed no early success, Summit shares dropped 24% the following day. Richter believes Chinese pharmaceutical companies collaborating with Western firms can become next-generation multinational players and should be viewed as biotech investment opportunities.

Korean Source

This article is an English localization of a Korean-language crypto news report. Original headline: 골드만삭스, 중국 바이오…빅파마 쇼핑처